Apellis Pharmaceuticals, Inc. ("Apellis") is pleased to offer the Retina Fellow Research Grant, with a value of up to $50,000, awarded based on the project's scientific merit and impact on patients with geographic atrophy (GA) due to age-related macular degeneration. 
Before beginning the application, please review the detailed instructions and required application materials by clicking here:

Research Focus:

Apellis is committed to improving the lives of patients with geographic atrophy and supports medical and scientific research that demonstrates the highest standards of scientific integrity, inclusivity, and intellectual curiosity. Submitted projects should focus on at least one of the following areas:

  • Development of studies and tests to evaluate visual function in patients with GA due to AMD.
  • Further understanding of the relationship between GA and neovascular AMD.
  • Real world effectiveness of pegcetacoplan in patients with GA due to AMD.
  • Effectiveness and safety of pegcetacoplan in patients with GA secondary to AMD with clinical features (phenotypes) not assessed in clinical trials (including but not limited to: bilateral GA patients treated in both eyes; GA patients with lesions approximately 200 microns or further from the foveal center).
  • Effectiveness and safety of pegcetacoplan in GA due to AMD with different dosing intervals and dose escalation or de-escalation.

Review Process: 

Applications to the Apellis US Retina Fellow Research Grant will be reviewed on a rolling basis up until the submission deadline on August 28, 2026. At the submission deadline, applications will be de-identified and reviewed based on the research merit criteria and alignment with the Apellis scientific areas of interest.

Timeline: 

Following closure of the submission portal on August 28, applications will be reviewed as outlined above. The process is anticipated to take 3-4 weeks, at which point the applicant(s) with the selected submission will be notified. Following confirmation with the selected applicant, an announcement will be made regarding the selected project.

 

The deadline for applications is August 28, 2026, at 11:59 PM ET. Any application submitted after the deadline will not be considered.

Click the button below to begin your application!  

On behalf of Apellis, MEDUCOM Health Inc. will collect information in this submission portal to aid with collection of application for the US Retina Fellows Grant. The following personal data will be collected: Name, location, contact information, information on current fellowship, CV, and any other pertinent documents for the application. All information will be stored and transferred securely between MEDUCOM and Apellis,  in compliance with privacy standards for the sole purpose of the US Retina Fellows Grant. Your information will never be sold or shared with third parties and will be securely retained only as long as necessary to fulfill the purposes of this meeting. We are committed to protecting your privacy and ensuring the confidentiality of your information throughout this process.

When submitting, please ensure all applications are submitted in full. You will not be able to return to partially completed submissions.  

For more information, contact grantsandgiving@apellis.com or Connect with an MSL/Apellis Medical Hub